Risk adapted chemoprevention for prostate cancer: an option?

Area of Science:

• Oncology
• Urology
• Preventive Medicine

Background:

• Prostate cancer diagnosis and treatment present challenges due to high prevalence, late-onset presentation, slow progression, and significant costs.
• Effective disease prevention strategies are needed to mitigate these challenges.

Purpose of the Study:

• To review the risks, benefits, and health economic aspects of prostate cancer chemoprevention.
• To evaluate the efficacy of 5-α reductase inhibitors and other compounds for prostate cancer prevention.

Main Methods:

• Analysis of two randomized controlled studies on 5-α reductase inhibitors (finasteride, dutasteride) for prostate cancer chemoprevention (Level of Evidence 1).
• Review of evidence for other potential chemopreventive agents, including SERMs, NSAIDs, and statins.
• Consideration of health economic factors associated with chemoprevention.

Main Results:

• 5-α reductase inhibitors are proven effective for prostate cancer chemoprevention in both low- and high-risk individuals.
• Other compounds like SERMs, NSAIDs, and statins show potential efficacy.
• Chemoprevention in high-risk cohorts using 5-α reductase inhibitors is a viable and potentially cost-effective option.

Conclusions:

• Chemoprevention, particularly with 5-α reductase inhibitors, offers a promising strategy for prostate cancer management.
• Further open and unbiased exploration of chemoprevention options for prostate cancer is warranted.
• The use of 5-α reductase inhibitors in high-risk populations is a practical and potentially cost-effective approach.